FDA Clears Invokana for CV Prevention in T2D
(MedPage Today) -- First oral diabetes drug to win this indication (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 31, 2018 Category: American Health Source Type: news
FDA Clears Canagliflozin for CV Prevention in T2D
(MedPage Today) -- First oral diabetes drug to win this indication (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - October 31, 2018 Category: Endocrinology Source Type: news
U.S. FDA Approves INVOKANA(R) (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
INVOKANA® is now the only oral diabetes treatment approved to reduce the risk of these cardiovascular events
Approval aligns with ADA and AACE treatment guidance and supports use of INVOKANA® across a broad range of patients
TITUSVILLE, N.J.,... Biopharmaceuticals, Endocrinology, Cardiology, FDA Janssen Pharmaceutical, INVOKANA, canagliflozin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 30, 2018 Category: Pharmaceuticals Source Type: news
U.S. FDA Approves INVOKANA ® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 30, 2018 Category: Pharmaceuticals Source Type: news
FDA Approves Invokana (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
TITUSVILLE, NJ, October 30, 2018– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Invokana (canagliflozin) to reduce the risk of major adverse... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 30, 2018 Category: Drugs & Pharmacology Source Type: news
SGLT2 Inhibitor-Amputation Link in Diabetes -- Is it Hypovolemia? SGLT2 Inhibitor-Amputation Link in Diabetes -- Is it Hypovolemia?
Observational study finds an increased amputation risk with diuretic use in people with diabetes, suggesting that the hypovolemic mechanism may also explain the amputation risk seen with canagliflozin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
EU Okays CV Benefit Labeling for Canagliflozin in Diabetes EU Okays CV Benefit Labeling for Canagliflozin in Diabetes
The European label for the SGLT2 inhibitor canagliflozin for type 2 diabetes will now include positive cardiovascular benefit results from the CANVAS trial, while a decision from the US FDA is forthcoming.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
How One Class Of Diabetes Medications May Lead To Flesh-Eating Genital Infections
If you are taking canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, or any other sodium-glucose cotransporter-2 (SGLT2) inhibitor, you may want to pay attention to this FDA warning. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 1, 2018 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news
Another SGLT2 That You Can Feel Safe Prescribing Another SGLT2 That You Can Feel Safe Prescribing
In regard to amputation risk (and despite a black box warning), it appears that canagliflozin is no less safe than other diabetes drugs.Medscape Internal Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 27, 2018 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news
Trulicity Label Update; Canagliflozin Success for CKD; Capsaicin for Weight Loss
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 20, 2018 Category: Cardiology Source Type: news
Canagliflozin Renal Outcomes Study Is Halted Early for Efficacy Canagliflozin Renal Outcomes Study Is Halted Early for Efficacy
Hope that observed renoprotective effects of SGLT2 inhibitors will delay worsening of kidney disease in type 2 diabetes seems to be borne out, as the CREDENCE trial is stopped early.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 17, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA ® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 16, 2018 Category: Pharmaceuticals Source Type: news
U.S. FDA Extends Review Timeline for INVOKANA ® (canagliflozin) Supplemental New Drug Application
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 13, 2018 Category: Pharmaceuticals Source Type: news
New Study Finds No Link Between Canagliflozin and Amputations New Study Finds No Link Between Canagliflozin and Amputations
A large observational study offers reassurance following the doubling of risk seen in CANVAS, although the investigator acknowledges amputations are still ' the fly in the ointment ' for this drug.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
No Greater Amputation Risk with Canagliflozin in T2D Patients
(MedPage Today) -- Real-world analysis done in over 100,000 canagliflozin users (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - June 24, 2018 Category: Pediatrics Source Type: news
